Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2008-10-30 Interim / Quarterly Rep…
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
Q3 Bericht 2008
Interim / Quarterly Report Classification · 100% confidence The document is a 'Zwischenbericht' (Interim Report) for MorphoSys AG covering the period from January to September 2008. It contains detailed financial statements, including the Consolidated Income Statement, Balance Sheet, Statement of Changes in Equity, and Cash Flow Statement, along with a management discussion and analysis (Konzern-Zwischenlagebericht). Since it provides comprehensive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. 9M 2008
2008-10-30 German
Danske Markets Equities’ and ESN’s Antibody Seminar
Investor Presentation Classification · 98% confidence The document is titled 'ESN's Antibody Seminar' and contains detailed slides covering company technology (HuCAL), pipeline status, financial details of major deals (Novartis), clinical development timelines (MOR103, MOR202), business segments, and guidance for 2008, including H1 2008 financial comparisons. This structure—a presentation format with slides, financial highlights, and strategic updates—is characteristic of an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K, nor is it a short announcement of a report (RPA/RNS). The content is designed to inform investors about the company's progress and outlook.
2008-09-30 English
Sal. Oppenheim’s 3. European Healthcare Investors Conference
Investor Presentation Classification · 98% confidence The document text is titled 'Sal. Oppenheim – European Healthcare Investors Conference 2008' and is dated September 3, 2008. The content consists of slides detailing company technology (HuCAL), business segments, active collaborations, timelines, and partnership financial details. This structure (conference presentation slides) strongly indicates a presentation given to investors or analysts at a specific industry event. Among the provided codes, 'Investor Presentation' (IP) is the most appropriate classification for materials used in an investor conference setting, which typically involves detailed slides on strategy, technology, and financials.
2008-09-05 English
Q2 Report 2008
Interim / Quarterly Report Classification · 100% confidence The document is titled '2nd Interim Report January – June 2008' and contains comprehensive financial statements, including the Consolidated Statement of Operations, Balance Sheet, Statement of Cash Flows, and Notes to the Interim Consolidated Financial Statements. It provides a detailed analysis of the company's financial performance for the six-month period, which fits the definition of an Interim/Quarterly Report (IR). H1 2008
2008-07-29 English
Q2 Bericht 2008
Interim / Quarterly Report Classification · 100% confidence The document is a 'Zwischenbericht' (Interim Report) for MorphoSys for the period January to June 2008. It contains comprehensive financial statements, including the consolidated income statement, balance sheet, cash flow statement, and management discussion and analysis (Konzern-Zwischenlagebericht). It is not an announcement of a report, but the report itself, containing substantive financial data for a period shorter than a full fiscal year. H2 2008
2008-07-29 German
Deutsche Bank German Corporate Conference
Investor Presentation Classification · 98% confidence The document text is titled '### Deutsche Bank German & Austrian Corporate Conference' and is dated 'June 5, 2008'. It contains detailed slides/sections on 'HuCAL: Leading Antibody Technology', 'Robust Intellectual Property', and 'Business Segments' including revenue figures and collaboration timelines. This structure, focusing on technology, IP, and business performance presented at a specific conference, strongly indicates an Investor Presentation (IP) or a presentation used during a conference call. Since it is a structured presentation format rather than a full transcript (CT) or a formal regulatory filing, Investor Presentation (IP) is the most appropriate classification. The length (29,037 chars) is substantial, suggesting it is the presentation content itself, not just an announcement of one.
2008-06-05 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.